Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dopamine agonist therapy in hyperprolactinemia.

J Webster1

  • 1Northern General Hospital, Sheffield, U.K.

The Journal of Reproductive Medicine
|January 29, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of recovery of sheep, goats, and calves from reversible electrical head-only and head-to-body stunning for halal meat production.

New Zealand veterinary journal·2024
Same author

Access to health care for people with stroke in South Africa: a qualitative study of community perspectives.

BMC health services research·2022
Same author

Indicators of dehydration in healthy 4- to 5-day-old dairy calves deprived of feed and water for 24 hours.

Journal of dairy science·2020
Same author

The dangers of dermal fillers.

The British journal of oral & maxillofacial surgery·2019
Same author

Case of a Painful Affection of the Arm, Following Venesection, Cured by Acupuncturation.

The London medical and physical journal·2018
Same author

The performance of surfactant mixtures at low temperatures.

Journal of colloid and interface science·2018
Same journal

Elective Procedures in Obstetrics and Gynecology During the COVID-19 Pandemic.

The Journal of reproductive medicine·2022
Same journal

Choriocarcinoma in Situ in a Partial Hydatidiform Mole A: Case Report.

The Journal of reproductive medicine·2018
Same journal

Isolated Recurrent Hematotrachelos After Abdominal Myomectomy A Case Report.

The Journal of reproductive medicine·2018
Same journal

Live Birth from Electively Cryopreserved Oocytes: A Feasible Option for Couples Opposed to Embryo Cryopreservation A Case Report.

The Journal of reproductive medicine·2018
Same journal

Prevalence and Risk Factors of Ejaculation Failure on the Day of Operation Among Chinese Males Undergoing Assisted Reproductive Technique Treatments.

The Journal of reproductive medicine·2018
Same journal

Efficacy and Safety of Perioperative Use of Epinephrine for Laparoscopic Myomectomy in Infertile Women with Symptomatic Solitary Intramural Uterine Fibroids A Randomized Clinical Trial.

The Journal of reproductive medicine·2018
See all related articles

Cabergoline and quinagolide offer advantages over bromocriptine for hyperprolactinemic disorders. Cabergoline is superior in efficacy and tolerability, making it the preferred treatment choice.

Area of Science:

  • Endocrinology
  • Pharmacology

Background:

  • Bromocriptine, a dopamine agonist, was a primary treatment for hyperprolactinemic disorders but had limitations.
  • Newer agents like cabergoline and quinagolide offer improved efficacy and tolerability.

Purpose of the Study:

  • To compare the efficacy and tolerability of newer dopamine agonists (cabergoline, quinagolide) with bromocriptine.
  • To determine the optimal treatment for hyperprolactinemic disorders.

Main Methods:

  • Comparative studies evaluating prolactin suppression and restoration of gonadal function.
  • Assessment of drug tolerability and side effect profiles.
  • Analysis of pharmacokinetic properties including plasma half-life.

Main Results:

Related Experiment Videos

  • Cabergoline demonstrated superior efficacy and tolerability compared to bromocriptine.
  • Quinagolide showed similar efficacy and better tolerability than bromocriptine.
  • Cabergoline exhibited a trend towards superior activity and better tolerability than quinagolide.

    • Conclusions:

    • Cabergoline is considered the treatment of choice for hyperprolactinemic men and women not seeking pregnancy.
    • Both cabergoline and quinagolide represent significant advancements in managing hyperprolactinemic disorders.